On October 31, 2023 Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, reported a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2023 38th Annual Meeting November 3-5, 2023 in San Diego, CA (Press release, Replicate Bioscience, OCT 31, 2023, View Source [SID1234636578]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Precision immuno-oncology (PIO) is Replicate’s novel approach to targeting predictable resistance mutations, which arise when cancer cells evolve to evade therapies. RBI–1000 is an srRNA precision immunotherapy candidate targeting acquired resistance mutations (ARM) in estrogen receptor positive (ER+) firstline, metastatic breast cancer, which is the most common type of metastatic breast cancer. RBI-1000 leads to tumor control with the elimination of tumor cells expressing ARM in preclinical models. RBI-3000 is an srRNA PIO program targeting acquired resistance to current tyrosine kinase inhibitor standard of care therapy for metastatic EGFRm+ non-small cell lung cancer.
"When combined with standard of care, RBI-1000 induces synthetic immune lethality: a lose-lose scenario in which the tumor is forced to either remain the same and be eliminated by the targeted therapeutic or mutate and be destroyed by srRNA-trained immune cells," said Zelanna Goldberg, M.D., Chief Medical Officer at Replicate and poster presenter. "Our srRNA oncology programs are being developed to harness the power of the body’s own cells to train the immune system to destroy the treatment resistant tumor clones and produce durable therapeutic benefit. We are pleased to share the latest progress on our oncology programs with the SITC (Free SITC Whitepaper) community."
Details for the poster presentation is as follows:
Title: Self-replicating RNA therapeutics for Off-the-Shelf Precision Immunotherapy targeting acquired resistance mutations in low TMB tumors
Abstract Number: 876
Type of Presentation: Poster Presentation
Date & Time: Saturday, November 4; 9 a.m. – 8:30 p.m.
The abstract can be found on the SITC (Free SITC Whitepaper) Annual Meeting website and the poster will be available on the Replicate website following presentation.